TransCode Therapeutics, Inc. (RNAZ) Earnings Call Transcripts
TransCode Therapeutics, Inc.'s Latest Earnings Call - June 18, 2026
In the second quarter of 2026, TransCode Therapeutics, Inc. (RNAZ:US) reported significant advancements in its clinical pipeline, particularly with its lead program, TTX-MC138, which is in Phase II trials for colorectal cancer. The company emphasized its commitment to targeting advanced tumors, with a focus on RNA-targeted therapeutics and immunotherapies. Revenue and earnings figures were not disclosed, but management highlighted a strong cash position of approximately $13 million as of March 31, 2026, and indicated potential for further funding through a $20 million equity financing arrangement. The management maintained a positive outlook, signaling upcoming catalysts including Phase IIa enrollment completion and preliminary data readouts in the next 18 months.
Reported metrics
| Metric | Value |
|---|---|
| Cash Position | $13M (inline) |
| Market Cap | $5M (negative) |
| Phase I Patient Count | 16 patients (positive) |
| Disease Stabilization Rate | 60% (positive) |
| Equity Financing Potential | $20M (positive) |
| Phase IIa Enrollment | Upcoming (positive) |
Guidance from management
Management maintained a positive outlook, signaling that they expect to complete Phase IIa enrollment and provide preliminary results within the next 18 months, while continuing to pursue funding opportunities to support their pipeline development.
What management said
Thank you very much, Keith. We hope that we were able to convey our vision and our passion for our company as we are fully anchored on our -- laser focused on TTX-MC138, as you have heard from Keith, the development and the execution in the context of our three shots on goal against advanced cancer. Our team is fully committed on executing on our goal to serve the needs of the patients, also our stakeholders and inve...
What analysts pressed on
Analysts expressed concerns regarding the company's market cap relative to its potential and the need for successful execution of clinical trials. There were questions about the timeline for upcoming catalysts and the overall competitive landscape in advanced cancer therapeutics.
Main topics on the call
- Pipeline Diversification — TransCode has expanded its pipeline with the addition of two new treatment modalities, including the cancer vaccine Seviprotimut-L and an oncolytic immunotherapy platform. CEO Philippe Calais stated, "we remain laser foc...
- Clinical Trial Progress — The Phase I trial for TTX-MC138 has shown promising results, with 60% of patients experiencing disease stabilization. Daniel Vlock noted, "the drug was well tolerated" and there were no dose-limiting toxicities observed,...
- Market Opportunity — Management highlighted a substantial market opportunity in advanced cancer treatments, with estimates suggesting a global market size of $120 billion to $250 billion by 2032. Philippe Calais remarked, "the market opportu...
- Financial Position — TransCode reported a cash position of approximately $13 million as of March 31, 2026, and is pursuing a $20 million equity financing arrangement. CFO Tom Fitzgerald stated, "we anticipate receipt of additional cash over ...
Read the full TransCode Therapeutics, Inc. transcript (June 18, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. (RNAZ) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 1 call on record spanning June 18, 2026 to June 18, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 1 TransCode Therapeutics, Inc. earnings call transcript on record, spanning June 18, 2026 to June 18, 2026. The most recent call on file is dated June 18, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RNAZ
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 1
- First call
- June 18, 2026
- Most recent
- June 18, 2026
| Quarter | Date | |
|---|---|---|
| Special Calls | Jun 18, 2026 | Read transcript → |